NCT03259087View on ClinicalTrials.gov

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

January 28, 2018

Study Completion Date

February 9, 2018

Conditions
Renal Impairment
Interventions
DRUG

MK-3866

Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.

Trial Locations (2)

32809

Orlando Clinical Research Center ( Site 0002), Orlando

33014

Clinical Pharmacology of Miami ( Site 0001), Hialeah

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) | Biotech Hunter | Biotech Hunter